← Leaderboards
Terry S Elton
Ohio State University
$3,572,815
Attributed
$5,039,892
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $625.9K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,039,892 · 4
By mechanism
R01$3,869,052 · 2
T32$742,321 · 1
R21$428,519 · 1
Top collaborators
- Jack C. Yalowich5 shared
- Pamela A. Lucchesi3 shared
- Karl H Obrietan2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jack C. Yalowich$4,212,052
- Daniel R. Schoenberg$10,326,959
- Rama K Mallampalli$45,256,042
- Miguel Angel Villalona$9,621,601
- Paul K Herman$7,105,773
Others in their field
Top investigators on “Messenger Rna”
- Jeffrey P Krischer · University Of South Florida$206,732,287
- David Heimbrook · Leidos Biomedical Research, Inc.$96,474,613
- Henry F Chambers · Duke University$47,759,573
- Vance G Fowler · Duke University$46,487,462
- Barton F Haynes · Duke University$43,472,529
- Bradley F Boeve · Mayo Clinic Rochester$42,990,413
Research focus
Messenger RnaRna SplicingSiteProteinsTranscriptUntranslated RegionsProtein IsoformsAlternative SplicingExonsMediatingClinically RelevantAngiotensin IiAttenuatedInnovationComplexFutureTranslationsKnock-DownBaseClinical EfficacyAcquired Drug ResistanceAmino Acid SequenceCellsComplementary Dna
Grant awards (19)
Novel Topoisomerase II alpha isoform as a drug resistance determinant$349,713
R01 · FY2023 · CA
Novel Topoisomerase II alpha isoform as a drug resistance determinant$349,713
R01 · FY2022 · CA
Novel Topoisomerase II alpha isoform as a drug resistance determinant$356,850
R01 · FY2021 · CA
Novel Topoisomerase II alpha isoform as a drug resistance determinant$356,850
R01 · FY2020 · CA
Novel Topoisomerase II alpha isoform as a drug resistance determinant$350,189
R01 · FY2019 · CA
Training in Congenital and Acquired Heart Disease$288,608
T32 · FY2011 · HL
Training in Congenital and Acquired Heart Disease$284,201
T32 · FY2010 · HL
microRNA and Down Syndrome$227,044
R21 · FY2010 · HD · contact PI
Human Angiotensin II Receptor Gene Regulation$254,888
R01 · FY2009 · HL · contact PI
microRNA and Down Syndrome$201,475
R21 · FY2009 · HD · contact PI
Training in Congenital and Acquired Heart Disease$169,512
T32 · FY2009 · HL
Human Angiotensin II Receptor Gene Regulation$254,888
R01 · FY2008 · HL · contact PI
Human Angiotensin II Receptor Gene Regulation$254,888
R01 · FY2007 · HL · contact PI
Human Angiotensin II Receptor Gene Regulation$262,500
R01 · FY2006 · HL · contact PI
Human Angiotensin II Receptor Gene Regulation$224,250
R01 · FY2005 · HL
Human Angiotensin II Receptor Gene Regulation$224,250
R01 · FY2004 · HL
Human Angiotensin II Receptor Gene Regulation$219,000
R01 · FY2003 · HL
Human Angiotensin II Receptor Gene Regulation$219,000
R01 · FY2002 · HL
HUMAN ANGIOTENSIN II RECEPTOR GENE REGULATION$192,073
R01 · FY2000 · HL